ABSTRACT: An important role of the oncology nurse is to monitor and continually assess the patient for chemotherapy-induced peripheral neuropathy, which is a complication occurring in up to 90% of patients treated with neurotoxic chemotherapy agents. Severity and incidence depend on specifics of treatment and patient comorbidities and lifestyle factors. Symptoms vary widely and will adversely affect quality of life, but early intervention can prevent exacerbation and may restore neurological function. The case study discussed in this article illustrates the manifestations of neuropathy affecting sensory, autonomic, and motor function, and shows how both physical and mental health therapies can be effective. To support the cancer survivor during and after chemotherapy, the oncology nurse will manage neurological impairment by examination, grading systems, pharmacological and nonpharmacological approaches, and patient education and referrals.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most challenging and complex complications of cancer chemotherapy. Peripheral neuropathy is a disturbance of function or pathological change in a nerve or nerves, and CIPN generally is diffuse and bilateral, resulting from systemic toxicity to nerves. Several classes of chemotherapeutic drugs cause peripheral neuropathy, including the plant alkaloids (vincristine and vinblastine), taxanes (paclitaxel and docetaxel [Taxotere]), platinum-based compounds (cisplatin, carboplatin, and oxaliplatin [Eloxatin]), and other drugs, such as thalidomide.
The incidence and severity of CIPN vary considerably for each peripherally neurotoxic agent when administered alone or in combination, but for vincristine, cisplatin, oxaliplatin, and paclitaxel, estimates for the occurrence of CIPN are as high as 70% to 90%.[2–6] As many as 60% of patients receiving docetaxel and 40% of those treated with carboplatin develop CIPN.[3,7] The development of both short- and long-term CIPN is highly dependent on factors such as age, single dose intensity, cumulative dose, duration of therapy, combinations of neurotoxic agents, coexisting neuropathies (for example, diabetic neuropathy), genetic susceptibility, and alcohol abuse.[8–14]
Exact mechanisms for CIPN are not clearly understood; however, studies indicate that it is related to axonal damage of peripheral nerves, causing dysfunctional effects in primary afferent fibers that give rise to abnormal impulse transmission, nerve hyperexcitability, spontaneous or ectopic discharge from nerves, and pain.[15–18] Neurotoxic effects of chemotherapy target the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures of peripheral nerves.
The onset, severity, characteristics, and duration of clinical manifestations of CIPN are highly variable. Typically, CIPN is characterized by a glove-and-stocking distribution in the hands and feet with sensory loss or hypersensitivity, and in some cases motor and autonomic dysfunction. Symptoms include paresthesia (an abnormal sensation such as numbness or tingling, spontaneous or evoked, and not unpleasant), dysesthesia (an unpleasant abnormal sensation, spontaneous or evoked), allodynia (pain from stimuli that are not typically painful, such as touch), hyperalgesia (exaggerated pain in response to stimuli that are typically painful), hypoalgesia (diminished pain response to a typically painful stimulus), or pain that is burning, shooting, or electric-shock–like.
Patients also may experience a loss of temperature sensation, of proprioception, and of vibratory sensing; weakness in their extremities; or ataxia. Sensory and motor disturbances are often a function of specific chemotherapy agents. For example, paclitaxel can induce sensory impairment and pain, whereas vincristine may produce a sensorimotor neuropathy and motor dysfunction such as foot drop. Motor and autonomic nervous system involvement is typically seen with vincristine and platinum-based compounds.
Several grading systems are used to classify the severity of CIPN. Among the most common are the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE) and the Eastern Cooperative Oncology Group Neuropathy Scale. Both measure sensory and motor abnormalities on a grading scale of 0 (absent) to 4 (severe) based on findings from physical examination and patient reports.[21–23]
The Total Neuropathy Scale (TNS) is less frequently used in clinical practice, but is much more comprehensive. The TNS measures sensory and motor symptoms, pin sensibility, vibration sensibility, and reflexes, and it incorporates information from quantitative sensory testing (QST) and electromyography to quantify autonomic symptoms, thermal and vibration thresholds, and nerve signal amplitudes. The TNS demonstrates greater sensitivity to sensory and motor problems, and more precisely quantifies changes over time. More information about these and other scales to assess peripheral neuropathy is provided online by the Oncology Nursing Society.
The incidence and severity of CIPN related to specific cancer chemotherapy regimens have been well studied; however, less is known about the clinical course of CIPN and its long-lasting effects on cancer survivors’ daily function and quality of life (QoL). CIPN can be a persistent and debilitating problem. Follow-up care for cancer survivors must include ongoing monitoring for CIPN, especially if patients experience this problem during therapy. Early and aggressive treatment with analgesics and supportive interventions (eg, physical and occupational therapy) may help to prevent worsening of painful and debilitating CIPN and long-term QoL consequences.
The patient, “JB,” is a 38-year-old premenopausal female with insulin-controlled type-2 diabetes. She was diagnosed with invasive ductal carcinoma of the right breast in 2007. Based on the American Joint Committee on Cancer TNM staging system, her tumor was staged at T (tumor size), T2, 2.5 cm; N (nodal status), spread to lymph nodes, 2 of 5; and M (metastases), M0 (no evidence of distant disease). Receptor assays indicated that her tumor was estrogen receptor (ER) positive, progesterone receptor (PR) positive, and human epidermal growth factor receptor 2 (HER2) positive
She underwent a radical right mastectomy followed by reconstructive surgery with a TRAM (transverse rectus abdominus myocutaneous) flap. After recovering from surgery, she was treated with a chemotherapy regimen that included four cycles of dose-dense doxorubicin at 60 mg/m2 and cyclophosphamide at 600 mg/m2 every 2 weeks, followed by weekly paclitaxel at 80 mg/m2 for 12 weeks and trastuzumab (Herceptin) given as a 4 mg/kg loading dose in the first week and then at 2 mg/kg weekly for 12 weeks. Therapy with tamoxifen was initiated, and she completed an adjuvant regimen with trastuzumab at 6 mg/kg every 3 weeks for 1 year.
With her eleventh dose of paclitaxel, JB had evidence of a Grade 3 sensory neuropathy by the NCI CTCAE grading system (sensory alteration or paresthesia interfering with activities of daily living) and Grade 1 motor neuropathy (asymptomatic, with weakness detected on examination or by testing only). A decision was made to continue therapy with the last course of treatment.
JB now presents to the oncology clinic for follow-up, complaining that over the past 8 months she has had difficulty walking. Her oncology nurse obtains specific information about how JB has been doing over the last 6 months. JB reports feeling as though her balance is off and describes a constant burning discomfort in her hands and feet. Occasionally, she experiences sharp, shooting, and electric-shock–like pains in her feet. She also says that she has had constant burning sensations in her hands and feet since completing her chemotherapy.
JB neglected to report these symptoms during prior follow-up visits because she hoped that these sensory and motor experiences would resolve after therapy. This did not happen, and her symptoms have worsened to the point that it is uncomfortable for her to wear shoes and walk. She states that it is often difficult to start walking when she has been seated for extended periods of time, and her legs feel weak and heavy. She is also disturbed by “pins and needles” sensations in her hands, and finds herself dropping things.
At times, she has difficulty with fine motor movements, and touch causes pain in her fingertips, interfering with her ability to write, use a computer at work, and correspond on her Blackberry. JB tells her oncology nurse that she is frightened, frustrated, and depressed over her current situation. She admits that she cries frequently, is unable to sleep, and has no energy. JB believes that her level of function has declined and these distressing symptoms have significantly affected her quality of life and ability to work; however, she is still able to care for her family.
She denies any symptoms of fever, chills, headache, cough, chest pain, nausea, vomiting, or diarrhea, and has no history of trauma to her back or extremities. Her health history is significant for type 2 diabetes diagnosed 8 years ago, during the last trimester of her pregnancy. Health records from her primary care physician indicate that she has not achieved adequate glycemic control, with glycated hemoglobin levels (A1C) in the range of 7.8% to 8.6% in the past 6 months. Also, 13 years ago, she had Lyme disease, which was treated with a course of doxycycline. She denies alcohol or illicit drug use but still continues to smoke about 1 pack of cigarettes per week. She lives with her husband and 8-year-old son, and is currently on medical leave of absence from her job as a paralegal.
Financial Disclosure: The author has no signifi
cant fi nancial interest or other relationship
with the manufacturers of any products
or providers of any service mentioned in
1. Merskey H, Bogduk N (eds): Classification of Chronic Pain, 2nd ed, Part III. IASP Task Force on Taxonomy, IASP Press, Seattle, 1994, pp 209–214.
2. Polomano RC, Bennett GJ: Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2(1):8–14, 2001.
3. Armstrong T, Almadrones L, Gilbert MR: Chemotherapy induced peripheral neuropathy. Oncol Nurs Forum 32(2):305–311, 2005.
4. Hausheer FH, Schilsky RL, Bain S, et al: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15–49, 2006.
5. Wilkes G: Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162–173, 2007.
6. Argyriou AA, Polychronopoulos P, Iconomou G, et al: A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377, 2008.
7. Wampler MA, Hamolsky D, Hamel K, et al: Case report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs 9(2):189–193, 2005.
8. Visovsky C: Chemotherapy-induced peripheral neuropathy. Cancer Invest 21(3):439–451, 2003.
9. Repetto L: Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1(4 Suppl 2):18–24, 2003.
10. Dropcho EJ: Neurotoxicity of cancer chemotherapy. Semin Neurol 24(4):419–426, 2004.
11. Kannarkat G, Lasher EE, Schiff D: Neurologic complications of chemotherapy agents. Curr Opin Neurol 20(6):719–725, 2007.
12. Argyriou AA, Koltzenburg M, Polychronopoulos P, et al: Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66(3):218–228, 2008.
13. McWhinney SR, Goldberg RM, McLeod HL: Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8(1):10–16, 2009.
14. Nurgalieva Z, Xia R, Liu CC, et al: Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther May 15, 2009 [Epub ahead of print].
15. Cata JP, Weng HR, Lee BN, et al: Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anesthesiol 72(3):151–169, 2006.
16. Dougherty PM, Cata JP, Burton AW, et al: Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 33(2):166–179, 2007.
17. Xiao WH, Bennett GJ: Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 135(3):262–270, 2008.
18. Park SB, Krishnan AV, Lin CS, et al: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15(29):3081–3094, 2008.
19. Malik B, Stillman M: Chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 12(3):165–174, 2008.
20. Dropcho EJ: Neurotoxicity of cancer chemotherapy. Semin Neurol 24(4):419–426, 2004.
21. Common Terminology Criteria for Adverse Events (CTCAE). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Version 4, May 2009. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev4.pdf. Accessed on June 1, 2009.
22. Postma T, Heimans J: Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11(5):509–513, 2000.
23. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655, 1982.
24. Cavaletti G, Frigeni B, Lanzani F, et al: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute Common Toxicity Scale.
J Peripher Nerv Syst 12(3):210–215, 2007.
25. Oncology Nursing Society: Measuring Oncology Nursing-Sensitive Patient Outcomes: Evidence-based Summary. Chemotherapy-induced Peripheral Neuropathy. Available at: http://www.ons.org/outcomes/Clinical/pdf/NeuropathySummary.pdf. Accessed on June 2, 2009.
26. Polomano RC, Farrar JT: Pain and neuropathy in cancer survivors. Surgery, radiation, and chemotherapy can cause pain: Research could improve its detection and treatment. Am J Nurs 106(3 Suppl):39–47, 2006.
27. Visovsky C, Collins M, Abbott L, et al: Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11(6):901–913, 2007.
28. Vahdat L: Choosing a taxane for adjuvant treatment of breast cancer: More than a flip of the coin? Natl Clin Pract Oncol 5(10):570–571, 2008.
29. Mielke S, Mross K, Gerds TA, et al: Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 14(10):785–792, 2003.
30. Tsavaris N, Kopterides P, Kosmas C, et al: Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: A pilot study. Pain Med 9(8):1209–1216, 2008.
31. Rao RD, Michalak JC, Sloan JA, et al: North Central Cancer Treatment Group: Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110(9):2110–2118, 2007.
32. Quilici S, Chancellor J, Löthgren M, et al: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol (online) 9:6, 2009.
33. Arnstein P: Chronic neuropathic pain: Issues in patient education. Pain Manag Nurs 5(4 Suppl 1):34–41, 2004.
34. Abramson Cancer Center of the University of Pennsylvania, OncoLink: Managing Symptoms: Peripheral Neuropathy (Nerve Damage). Available at: http://www.oncolink.com/coping/article.cfm?c=5&s=27&ss=52&id=577. Accessed on May 29, 2009.
35. Cavaletti G, Zanna C: Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38(14):1832–1837, 2002.
36. Savarese DM, Savy G, Vahdat L, et al: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29(6):501–513, 2003.
37. Albers J, Chaudhry V, Cavaletti G, et al: Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev Jan 24(1):CD005228, 2007.
38. Argyriou AA, Chroni E, Koutras A, et al: Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 64(1):26–31, 2005.
39. Argyriou AA, Chroni E, Koutras A, et al: A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: Final results. Support Care Cancer 14(11):1134–1140, 2006.
40. Argyriou AA, Chroni E, Koutras A, et al: Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of vitamin E supplementation. J Pain Symptom Manage 32(3):237–244, 2006.
41. Armstrong CM, Cota G: Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci USA 96(7):4154–4157, 1999.
42. Wolf S, Barton D, Kottschade L, et al: Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 44(11):1507–1515, 2008.
43. Cavaletti G, Zanna C: Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38(14):1832–1837, 2002.
44. Ocean AJ, Vahdat LT: Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625, 2004.
45. Gordon DB, Love G: Pharmacological management of neuropathic pain. Pain Manag Nurs 5(Suppl 1):19–33, 2005.
46. Dworkin RH, O’Connor AB, Backonja M, et al: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 132(3):237–251, 2007.
47. Cata JP, Cordella JV, Burton AW, et al: Spinal cord stimulation relieves chemotherapy-induced pain: A clinical case report. J Pain Symptom Manage 27(1):72–78, 2004.
48. Rock E, DeMichele A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133(11 Suppl 1):3785S–3793S, 2003.